Shopping Cart 0
Cart Subtotal
USD 0

Pyelonephritis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pyelonephritis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis-Pipeline Review, H2 2017, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 5, 2 and 1 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pyelonephritis-Overview

Pyelonephritis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pyelonephritis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pyelonephritis-Companies Involved in Therapeutics Development

Achaogen Inc

AstraZeneca Plc

Meiji Seika Pharma Co Ltd

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

The Medicines Company

Zavante Therapeutics Inc

Pyelonephritis-Drug Profiles

(avibactam + ceftazidime)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem + vaborbactam)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAI-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nacubactam-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pyelonephritis-Dormant Projects

Pyelonephritis-Discontinued Products

Pyelonephritis-Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam

Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis

Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016

Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016

Jun 02, 2016: Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections

Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin

Apr 07, 2016: Merck To Present Data on ZERBAXA at ECCMID 2016

Feb 22, 2016: New Antibiotic Against Drug-Resistant Bacteria Now Available

Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections

Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)

Jun 18, 2014: MerLion completes recruitment in Finafloxacin phase II cUTI trial

Aug 22, 2013: FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma's Lead Antibacterial Candidate Finafloxacin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Pyelonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pyelonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pyelonephritis-Pipeline by Achaogen Inc, H2 2017

Pyelonephritis-Pipeline by AstraZeneca Plc, H2 2017

Pyelonephritis-Pipeline by Meiji Seika Pharma Co Ltd, H2 2017

Pyelonephritis-Pipeline by Merck & Co Inc, H2 2017

Pyelonephritis-Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017

Pyelonephritis-Pipeline by The Medicines Company, H2 2017

Pyelonephritis-Pipeline by Zavante Therapeutics Inc, H2 2017

Pyelonephritis-Dormant Projects, H2 2017

Pyelonephritis-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pyelonephritis Therapeutic Products under Development, Key Players in Pyelonephritis Therapeutics, Pyelonephritis Pipeline Overview, Pyelonephritis Pipeline, Pyelonephritis Pipeline Assessment


Companies

Achaogen Inc

AstraZeneca Plc

Meiji Seika Pharma Co Ltd

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

The Medicines Company

Zavante Therapeutics Inc